资讯

The Pharma Letter10 小时
High costs and limited access threaten progress in HIV treatment despite new drug advances
Despite major strides in antiretroviral therapy (ART), the human immunodeficiency virus (HIV) market still faces serious ...
FDA approves new twice-yearly HIV shot. What to know
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
Frontiers1 天
Evolution of antiretroviral therapy: Transitioning from three-drug to two-drug HIV regimens
The field of HIV treatment has witnessed a significant transformation since the mid-1990s with the introduction of combination antiretroviral therapy ...
Mirage News5 天
FDA Approves Biannual HIV Prevention Injection
Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...
Discover Magazine on MSN11 天
FDA Approves Breakthrough HIV Drug, but It Could Be Hard to Access
Learn more about lenacapavir, the most effective HIV treatment and prevention drug, and how its cost could cause a setback.
Rolling Out12 天
99.9% breakthrough transforms HIV prevention forever
FDA approves Yeztugo HIV prevention injection showing 96% efficacy in clinical trials, but $14,000 cost creates significant ...
FDA approves twice-a-year injection for HIV prevention
A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...
FDA Approves ‘Breakthough’ Drug to Prevent HIV
In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.